DENVER — Covidien, a leading global healthcare products company and innovator in mechanical ventilation and respiratory care devices, announces the Zap VAP Recognition Program. This program will publicly recognize hospitals that have successfully reduced their ventilator-associated pneumonia (VAP) rates.
VAP is considered one of the most serious and costly hospital-acquired infections. In the United States, VAP is estimated to result in $1.5 billion in excess expenditures and 1.75 million additional hospital days each year.
“We value the efforts of the teams and individuals who work daily at hospitals and medical centers to reduce VAP,” said Michael Vannier, director of marketing for Covidien’s respiratory care business. “With the Zap VAP program, Covidien is committing resources to improve patient outcomes by empowering physicians and the healthcare community through the sharing of information that highlights best practices.”
To be considered a Zap VAP Center of Excellence, a facility must meet criteria that include the implementation of a VAP reduction program for the prior six months.
All Zap VAP Centers of Excellence were recognized at a reception held at the annual meeting of the Association for Professionals in Infection Control (APIC) in Denver June 16. Special recognition was planned for those facilities that have achieved a zero-VAP rate over the last 12 months in at least one clinical unit.
Source: Covidien
CDC Strategies Preventing Hospital-Onset C difficile Effectiveness Inconclusive in Testing
April 15th 2024Hospitals using CDC prevention strategies had different incidences of hospital-associated Clostridioides difficile infection compared to those that didn't, but the reasons are not necessarily the strategies themselves.